LC–MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column

  • Pursley J
  • Shen J
  • Schuster A
 et al. 
  • 12


    Mendeley users who have this article in their library.
  • 17


    Citations of this article.


BACKGROUND: apixaban (BMS-562247) (Eliquis((R))) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. METHODOLOGY/RESULTS: A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC-MS/MS. Run times were approximately 3 min. The lower limit of quantification (LLOQ) was 1.00 ng/ml for BMS-562247 and 5.00 ng/ml for BMS-730823. Intra- and inter-assay precision values for replicate QC control samples were within

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Janice Pursley

  • Jim X Shen

  • Alan Schuster

  • Oanh T Dang

  • Jim Lehman

  • Michael H Buonarati

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free